Synthesis of N-(6-(4-(Piperazin-1-yl)phenoxy)pyridin-3-yl)benzenesulfonamide Derivatives for the Treatment of Metabolic Syndrome.

• Type of Material: Article
• Authors: Nabajyoti Deka, Piramal Life Sciences Limited; Swapnil Bajare, Lupin Limited; Jessy Anthony, Piramal Life Sciences Limited; Amrutha Nair, Piramal Life Sciences Limited; Anagha Damre, Piramal Life Sciences Limited; Dharmeshkumar Patel, Emory University; Chandrika B-Rao, Piramal Life Sciences Limited; H. Sivaramakrishnan, Piramal Life Sciences Limited; Shivaprakash Jagalur Mutt, Piramal Life Sciences Limited; Chandan Wilankar, Piramal Life Sciences Limited; Rosalind Marita, Haffkine Institute for Training
• Language: English
• Date: 2013
• Publisher: Hindawi
• Publication Version: Final Published Version
• Copyright Statement: © 2013 Nabajyoti Deka et al.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1155/2013/201580
• Title of Journal or Parent Work: International Journal of Medicinal Chemistry
• Volume: 2013
• Start Page: 201580
• End Page: 201580
• Keywords: glucose; type 2 diabetes; risk; insulin; high plasma levels; cardiovascular disease; metabolic syndrome
• Research Categories: Chemistry, Pharmaceutical; Biology, Physiology

Abstract

Metabolic syndrome is a widely prevalent multifactorial disorder associated with an increased risk of cardiovascular disease and type 2 diabetes mellitus. High plasma levels of insulin and glucose due to insulin resistance are a major component of the metabolic disorder. Thiazolidinediones (TZDs) are potent PPARγ ligand and used as insulin sensitizers in the treatment of type 2 diabetes mellitus. They are potent insulin-sensitizing agents but due to adverse effects like hepatotoxicity, a safer alternative of TZDs is highly demanded. Here we report synthesis of N-(6-(4-(piperazin-1-yl)phenoxy)pyridin-3-yl)benzenesulfonamide derivatives as an alternate remedy for insulin resistance.